Standard BioTools Inc. (NASDAQ:LAB) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its holdings in shares of Standard BioTools Inc. (NASDAQ:LAB) by 14.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 246,951 shares of the company’s stock after selling 40,593 shares during the period. Legal & General Group Plc’s holdings in Standard BioTools were worth $432,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LAB. Takeda Pharmaceutical Co. Ltd. acquired a new stake in Standard BioTools in the 4th quarter worth about $29,000. Cibc World Markets Corp acquired a new position in shares of Standard BioTools during the 4th quarter worth approximately $48,000. Simon Quick Advisors LLC acquired a new stake in shares of Standard BioTools in the fourth quarter valued at approximately $54,000. KLP Kapitalforvaltning AS purchased a new position in Standard BioTools during the fourth quarter worth approximately $70,000. Finally, HighTower Advisors LLC lifted its position in Standard BioTools by 13.0% during the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after buying an additional 10,690 shares in the last quarter. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, KeyCorp downgraded Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Standard BioTools Price Performance

NASDAQ:LAB opened at $1.16 on Wednesday. The company’s 50-day moving average is $1.15 and its two-hundred day moving average is $1.56. Standard BioTools Inc. has a 1-year low of $0.97 and a 1-year high of $2.74. The firm has a market capitalization of $439.62 million, a price-to-earnings ratio of -1.63 and a beta of 1.54.

Insider Activity

In other Standard BioTools news, Director Casdin Partners Master Fund, L acquired 4,820,959 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average cost of $1.06 per share, with a total value of $5,110,216.54. Following the transaction, the director now owns 58,846,780 shares of the company’s stock, valued at $62,377,586.80. This trade represents a 8.92 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 53.10% of the company’s stock.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.